10/068,514 Application No.: REQUEST FOR CONTINUED EXAMINATION February 5, 2002 Filing Date: (RCE) TRANSMITTAL Granett, et al. First Named Inventor: Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, progress for continued examination of an utility or plant application Group Art Unit: filed on or after June 8, 1995. Examiner: D.A. Jagoe See The American Inventors Protection Act of 1999 (AIPA). P31824C1 Attorney Docket No.: **CERTIFICATE OF MAILING** I HEREBY CERTIFIY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, MAIL STOP: RCE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450. DATE: This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application. NOTE: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Final Rule, 65 Fed. Reg. 50092 (Aug 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20,2000) 1233 Off. Gaz. Pat. Office 47 (April 11, 2000), which established RCE practice. Submission required under 37 C.F.R. § 1.114 a.

□ Previously submitted i. Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on _____ (Any unentered amendment(s) referred to above will be entered) ii.

Consider the arguments in the Appeal Brief or Reply Brief previously filed on iii.

Other b. Enclosed 12/12/2003 DTESSEH1 00000144 10068514 i. Amendment/Reply 11 pages 01 FC:1801 770.00 DA ii. Affadavit(s)/Declaration(s) ____ pages iii. Information Disclosure Statement (IDS) _____ pages iv.

Form PTO 1449 ___ pgs. & ___ References v. E Return Receipt Postcard (MPEP 503) (specifically itemized) vi. 🗆 Other 2. Miscellaneous a.

Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103 (c)

CORRESPONDENCE ADDRESS

RESI ONDENCE ADDICESS

Address GLAXOSMITHKLINE

Corporate Intellectual Property – UW2220

P.O. Box 1539

King of Prussia, PA 19406-0939

Telephone (610) 270-5012 Facsimile (610) 270-5090

RESPECTFULLY SUBMITTED.

Vallendy of Nich

Signature Kathryn L/Sjebur

Registration No. 40,072



CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 ON DECEMBER 8, 2003

December 8, 2003

Attorney Docket No. P31824C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Granett, et al.

December 8, 2003

Appl'n No.:

10/068,514

Group Art Unit No.: 1614

Filed:

February 5, 2002

Examiner:

D.A. Jagoe

For:

COMPOSITION COMPRISING 5-[4-[2-(N-METHYL-N-2-

PYRIDYL)AMINO)ETHOXY]BENZYL]THIAZOLIDINE-2,4-DIONE

Mail Stop: RCE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

AMENDMENT PURSUANT TO 37 C.F.R. § 1.114

Sir:

Please amend the above-identified application as follows.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 7 of this paper.